| Molecular Weight: | 519.51 |
| Formula: | C19H20F3N5O5S2 |
| Purity: | ≥98% |
| CAS#: | 1450833-55-2 |
| Solubility: | DMSO up to 100 mM |
| Chemical Name: | methyl ((1S,2R,3S,4R)-2,3-dihydroxy-4-((2-(3-((trifluoromethyl)thio)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)cyclopentyl)sulfamate |
| Storage: | Powder:4oC 1 year. DMSO:4oC3 month;-20oC 1 year. |
Biological Activity:TAK-243 (MLN7243) is a potent, selective and cell permeable small molecule inhibitor of the ubiquitin activating enzyme (UAE) at nM range. The ubiquitin-activating enzymes, found more active in cancer cells than in normal healthy cells, catalyze the first step in ubiquitination reaction, targeting a protein for degradation via proteasome. TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways. TAK-243 treatment caused death of cancer cells and, in primary human xenograftstudies, demonstrated antitumor activity at tolerated doses. Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biology and for assessment of UAE inhibition as a new approach for cancer treatment. TAK-243 is now in phase I clinical trials for adult patients with advanced solid tumors. How to Use:In vitro:TAK-243 was suggested to be used at 1-10 µM final concentration in vitro and in cellular assays.In vivo: TAK-243 was administered intravenously at 12.5-25 mg/Kg to a panel of human-patient-derived and cell-line-derived xenograft (PDX and CDX, respectively) tumor models on a twice-per-week schedule. Reference:
- 1.Hyer ML, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. (2018) Nat Med. In press.
TAK-243_spec.pdfTAK-243_MSDS.pdf Products are for research use only. Not for human use.ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
